GeoVax Labs Inc
GOVX0.182USD
-0.009-4.72%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
5.40MMarket Cap
LossP/E TTM
More Details of GeoVax Labs Inc Company
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
GeoVax Labs Inc Info
Ticker SymbolGOVX
Company nameGeoVax Labs Inc
IPO dateApr 04, 1994
CEODodd (David A)
Number of employees17
Security typeOrdinary Share
Fiscal year-endApr 04
Address1955 Lake Park Drive
CitySMYRNA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code30080
Phone16783847220
Websitehttps://www.geovax.com/
Ticker SymbolGOVX
IPO dateApr 04, 1994
CEODodd (David A)
Company Executives of GeoVax Labs Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Dodd
Mr. David A. Dodd
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
36.18K
-1.32%
Mr. Mark W. Reynolds, CPA
Mr. Mark W. Reynolds, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
14.01K
--
Mr. Dean G. Kollintzas
Mr. Dean G. Kollintzas
Independent Director
Independent Director
6.67K
+733.50%
Dr. Randal D. Chase, Ph.D.
Dr. Randal D. Chase, Ph.D.
Independent Director
Independent Director
6.67K
+173.17%
Dr. Robert T. McNally, Ph.D.
Dr. Robert T. McNally, Ph.D.
Independent Director
Independent Director
3.60K
--
Dr. Kelly T. Mckee, M.D.
Dr. Kelly T. Mckee, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jayne Morgan, M.D.
Dr. Jayne Morgan, M.D.
Independent Director
Independent Director
--
--
Dr. Mark J. Newman, Ph.D.
Dr. Mark J. Newman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. John N. (Jack) Spencer, Jr.
Mr. John N. (Jack) Spencer, Jr.
Independent Director
Independent Director
--
--
Dr. John W. Sharkey, Ph.D.
Dr. John W. Sharkey, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Dodd
Mr. David A. Dodd
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
36.18K
-1.32%
Mr. Mark W. Reynolds, CPA
Mr. Mark W. Reynolds, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
14.01K
--
Mr. Dean G. Kollintzas
Mr. Dean G. Kollintzas
Independent Director
Independent Director
6.67K
+733.50%
Dr. Randal D. Chase, Ph.D.
Dr. Randal D. Chase, Ph.D.
Independent Director
Independent Director
6.67K
+173.17%
Dr. Robert T. McNally, Ph.D.
Dr. Robert T. McNally, Ph.D.
Independent Director
Independent Director
3.60K
--
Dr. Kelly T. Mckee, M.D.
Dr. Kelly T. Mckee, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 15
Updated: Mon, Dec 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
L1 Global Manager Pty Limited
3.41%
Sabby Management, LLC
2.23%
Armistice Capital LLC
1.23%
The Vanguard Group, Inc.
0.56%
Geode Capital Management, L.L.C.
0.48%
Other
92.09%
Shareholders
Shareholders
Proportion
L1 Global Manager Pty Limited
3.41%
Sabby Management, LLC
2.23%
Armistice Capital LLC
1.23%
The Vanguard Group, Inc.
0.56%
Geode Capital Management, L.L.C.
0.48%
Other
92.09%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.12%
Investment Advisor/Hedge Fund
3.02%
Hedge Fund
2.13%
Individual Investor
0.30%
Corporation
0.22%
Bank and Trust
0.18%
Research Firm
0.05%
Other
87.98%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
41
682.00K
2.30%
-857.24K
2025Q2
48
1.26M
5.17%
+95.79K
2025Q1
48
1.22M
8.27%
+83.76K
2024Q4
47
829.80K
9.13%
+330.71K
2024Q3
46
493.58K
6.02%
-230.53K
2024Q2
44
230.87K
6.14%
-94.40K
2024Q1
48
277.50K
12.08%
-7.33K
2023Q4
47
235.03K
12.03%
+67.17K
2023Q3
51
129.03K
7.28%
-172.28K
2023Q2
50
129.35K
7.40%
-168.66K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
115.16K
0.39%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
106.95K
0.36%
+9.91K
+10.22%
Jun 30, 2025
UBS Switzerland AG
106.77K
0.36%
+29.13K
+37.52%
Jun 30, 2025
Dodd (David A)
36.66K
0.24%
--
--
Jun 25, 2025
Spencer (John N Jr)
10.40K
0.07%
-1.00K
-8.77%
Jun 25, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 29, 2024
Merger
15→1
Jan 29, 2024
Merger
15→1
Jan 29, 2024
Merger
15→1
Jan 29, 2024
Merger
15→1
Date
Type
Ratio
Jan 29, 2024
Merger
15→1
Jan 29, 2024
Merger
15→1
Jan 29, 2024
Merger
15→1
Jan 29, 2024
Merger
15→1
FAQs
Who are the top five shareholders of GeoVax Labs Inc?
The top five shareholders of GeoVax Labs Inc are:
The Vanguard Group, Inc. holds 115.16K shares, accounting for 0.39% of the total shares.
Geode Capital Management, L.L.C. holds 106.95K shares, accounting for 0.36% of the total shares.
UBS Switzerland AG holds 106.77K shares, accounting for 0.36% of the total shares.
Dodd (David A) holds 36.66K shares, accounting for 0.24% of the total shares.
Spencer (John N Jr) holds 10.40K shares, accounting for 0.07% of the total shares.
The Vanguard Group, Inc. holds 115.16K shares, accounting for 0.39% of the total shares.
Geode Capital Management, L.L.C. holds 106.95K shares, accounting for 0.36% of the total shares.
UBS Switzerland AG holds 106.77K shares, accounting for 0.36% of the total shares.
Dodd (David A) holds 36.66K shares, accounting for 0.24% of the total shares.
Spencer (John N Jr) holds 10.40K shares, accounting for 0.07% of the total shares.
What are the top three shareholder types of GeoVax Labs Inc?
The top three shareholder types of GeoVax Labs Inc are:
L1 Global Manager Pty Limited
Sabby Management, LLC
Armistice Capital LLC
L1 Global Manager Pty Limited
Sabby Management, LLC
Armistice Capital LLC
How many institutions hold shares of GeoVax Labs Inc (GOVX)?
As of 2025Q3, 41 institutions hold shares of GeoVax Labs Inc, with a combined market value of approximately 682.00K, accounting for 2.30% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.88%.
What is the biggest source of revenue for GeoVax Labs Inc?
In --, the -- business generated the highest revenue for GeoVax Labs Inc, amounting to -- and accounting for --% of total revenue.
